Get the Stockscreener App
6.09
2.35%
0.14
Pre-market:
6.09
Verastem Inc Stock (VSTM) Latest News
The time has not yet come to remove your chips from the table: Verastem Inc (VSTM) - SETE News
Recent Insider Activity Could Benefit Verastem Inc (VSTM) - Knox Daily
Verastem CEO Dan Paterson sells shares worth $4,890 - MSN
Verastem, Inc. (NASDAQ:VSTM) Shares Acquired by JPMorgan Chase & Co. - Defense World
Verastem (NASDAQ:VSTM) Given New $9.00 Price Target at B. Riley - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Sees Large Increase in Short Interest - MarketBeat
Financial Metrics Check: Verastem Inc (VSTM)’s Ratios for Trailing Twelve Months - The Dwinnex
B. Riley Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) Stock - Defense World
Brokerages Set Verastem, Inc. (NASDAQ:VSTM) PT at $13.38 - MarketBeat
Vanguard Group Inc. Increases Stake in Verastem Inc. - GuruFocus.com
Verastem price target raised to $9 from $7 at B. Riley - MSN
B. Riley Adjusts Verastem's Price Target to $9 From $7, Maintains Buy Rating -January 31, 2025 at 09:19 am EST - Marketscreener.com
Verastem Licenses Investigational Cancer Drug VS-7375 from GenFleet, Shares Rise 4.1% – Market - HPBL
Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference - Yahoo Finance
Verastem Exercises Option for VS-7375 Targeting RAS Pathway Driven CancersVerastem, Inc. (NASDAQ:VSTM) has announced the exercise of its option with regards to VS-7375, which is an oral and selective KRAS G12D (ON/OFF) inhibitor. This move signif - Defense World
Guggenheim Reiterates Buy Rating for Verastem (NASDAQ:VSTM) - Defense World
Verastem's (VSTM) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Mizuho maintains Verastem stock outperform with $9 target By Investing.com - Investing.com Australia
Mizuho maintains Verastem stock outperform with $9 target - MSN
Cantor Fitzgerald Estimates Verastem FY2025 Earnings - Defense World
Verastem Stock Soars 46% After FDA Grants Priority Review for Cancer Treatment – Market - HPBL
Cantor Fitzgerald Forecasts Verastem FY2025 Earnings - MarketBeat
Verstem avutometinib and defactinib combo gains FDA priority review - Seeking Alpha
Verastem Expands Oncology Pipeline with VS-7375 Acquisition - TipRanks
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
Barclays PLC Acquires 47,094 Shares of Verastem, Inc. (NASDAQ:VSTM) - MarketBeat
KRAS Inhibitors Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Novartis, Verastem Oncology, Boehringer Ingelheim, Roche, Eli Lilly, Revolution Medicines - Barchart
Verastem appoints new COO with extensive biotech experience By Investing.com - Investing.com South Africa
Verastem appoints new COO with extensive biotech experience - Investing.com India
Verastem Appoints Matthew E. Ros as COO - TipRanks
Verastem Secures $150 Million Note Purchase Agreement with Oberland Capital - Defense World
Verastem stock retains Buy rating as KRASG12D program and LGSOC launch gain traction - Investing.com Canada
Verastem, Inc. (NASDAQ:VSTM) Shares Sold by Jane Street Group LLC - Defense World
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - BioSpace
Verastem Oncology Names Pharma Veteran Matthew Ros as COO Ahead of Key Cancer Drug Launch - StockTitan
Verastem Oncology Appoints Matthew E. Ros as Chief Operating Officer - Marketscreener.com
Dan Paterson Sells 8,568 Shares of Verastem, Inc. (NASDAQ:VSTM) Stock - MarketBeat
Verastem CEO sells shares worth $44,896 By Investing.com - Investing.com Australia
Verastem CEO sells shares worth $44,896 - Investing.com India
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):